Trump Administration Plans New Drug Pricing Deals With Biotech Firms

The Trump administration is preparing to announce a new round of drug-pricing agreements with midsize biotechnology companies on Monday, Bloomberg News reported Wednesday, citing people familiar with the matter.

The planned agreements would mark another step in U.S. President Donald Trump’s efforts to lower prescription drug prices and increase pressure on pharmaceutical and biotech companies to reduce costs for American patients.

According to the Bloomberg report, the upcoming deals are expected to involve midsize biotech companies, although the specific firms participating in the agreements were not immediately disclosed. Details about which medicines could be affected and the potential scale of the price reductions also remain unclear.

Reuters said it could not immediately independently verify the report.

Drug pricing has remained a major policy focus for the Trump administration as the White House seeks to address the comparatively high cost of prescription medicines in the United States. Any new agreements with biotechnology companies could broaden the administration’s drug-pricing initiative beyond larger pharmaceutical manufacturers and increase pressure across the industry.

The expected announcement could also attract attention from investors in biotech and pharmaceutical stocks. Drug-pricing policies can have significant implications for company revenue, profit margins and future investment in research and development, particularly for firms that depend heavily on a limited portfolio of high-value treatments.

Investors will be watching Monday’s announcement for details on the participating biotech companies, the drugs covered by the agreements and how the pricing arrangements will be implemented.

The latest development comes as the U.S. government continues to explore ways to reduce healthcare costs while maintaining access to new medicines and encouraging pharmaceutical innovation.

Until the administration formally announces the agreements, however, the scope and financial impact of the latest Trump drug-pricing initiative remain uncertain.